BRIEF published on 12/05/2025 at 18:39, 5 months 1 day ago Valneva Updates Share and Voting Rights as of November 2025 Stock Options Euronext Paris Voting Rights Valneva Double Voting Rights
BRIEF published on 12/05/2025 at 18:39, 5 months 1 day ago VALNEVA: Declaration of Shares and Voting Rights Euronext Paris Voting Rights Ordinary Shares Valneva 2025
BRIEF published on 12/05/2025 at 18:39, 5 months 1 day ago VALNEVA : Déclaration d'Actions et de Droits de Vote Euronext Paris Droits De Vote Actions Ordinaires Valneva 2025
PRESS RELEASE published on 12/05/2025 at 18:34, 5 months 1 day ago VALNEVA Declaration of shares and voting rights: November 30, 2025 VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form Euronext Paris Voting Rights Shares Valneva Double Voting Rights
PRESS RELEASE published on 12/05/2025 at 18:34, 5 months 1 day ago VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025 VALNEVA déclare des actions et des droits de vote, dont un passage en droit de vote double et un exercice d'options de souscription d'actions. Informations sur le siège social et le marché réglementé Euronext Paris Déclaration Droits De Vote Actions Valneva
BRIEF published on 12/03/2025 at 11:03, 5 months 4 days ago Valneva SE: Promising Developments in Lyme Disease Vaccine Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15
BRIEF published on 12/03/2025 at 11:03, 5 months 4 days ago Valneva SE : Développements prometteurs dans le domaine du vaccin contre la maladie de Lyme Valneva SE Vaccin Contre La Maladie De Lyme Prévisions Du Marché Pfizer VLA15
PRESS RELEASE published on 12/03/2025 at 10:58, 5 months 4 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation for Valneva SE, raising target price to €6.80. VLA15 vaccine progress and market potential analyzed Buy Recommendation Research Update Valneva SE Market Potential VLA15 Vaccine
BRIEF published on 11/04/2025 at 07:05, 6 months 3 days ago L'essai de phase 1 de Valneva donne des résultats positifs pour le vaccin contre le Zika Valneva Immunogénicité Essai De Phase 1 Adjuvant Vaccin Contre Le Zika
BRIEF published on 11/04/2025 at 07:05, 6 months 3 days ago Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine Phase 1 Trial Valneva Immunogenicity Zika Vaccine Adjuvant
Published on 05/07/2026 at 16:35, 1 hour 46 minutes ago Caledonia Mining Corporation Plc New Corporate Video
Published on 05/07/2026 at 15:15, 3 hours 6 minutes ago ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Published on 05/07/2026 at 14:35, 3 hours 46 minutes ago Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Published on 05/07/2026 at 14:30, 3 hours 51 minutes ago Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Published on 05/07/2026 at 14:30, 3 hours 51 minutes ago Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook
Published on 05/07/2026 at 18:00, 21 minutes ago Correction d’un communiqué du 05.05.2026 21:46 CET/CEST - E-PANGO: Composition du capital au 30 avril 2026
Published on 05/07/2026 at 17:45, 36 minutes ago Swiss Life shareholders approve all resolutions proposed by the Board of Directors
Published on 05/07/2026 at 17:45, 36 minutes ago Annual General Meeting of SKAN Group AG approves all proposals
Published on 05/07/2026 at 17:45, 36 minutes ago Results of Annual Shareholders Meeting of R&S Group Holding AG
Published on 05/07/2026 at 18:17, 4 minutes ago DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS LOUIS HACHETTE GROUP 2026-2027
Published on 05/07/2026 at 18:17, 4 minutes ago DESCRIPTION OF THE LOUIS HACHETTE GROUP SHARE BUYBACK PROGRAM 2026-2027
Published on 05/07/2026 at 18:01, 20 minutes ago LNA SANTE : Chiffre d'affaires du 1er trimestre 2026
Published on 05/07/2026 at 17:45, 36 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
